175 related articles for article (PubMed ID: 8768791)
1. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
[TBL] [Abstract][Full Text] [Related]
2. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
3. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
[TBL] [Abstract][Full Text] [Related]
4. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
Robbins JB; Schneerson R; Keith JM; Shiloach J; Miller M; Trollors B
Vaccine; 2007 Apr; 25(15):2811-6. PubMed ID: 17291636
[TBL] [Abstract][Full Text] [Related]
5. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
6. [Acellular pertussis vaccine].
Wiedermann G; Ambrosch F; Vanura H
Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
[TBL] [Abstract][Full Text] [Related]
7. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
8. New pertussis vaccination approaches: en route to protect newborns?
Locht C; Mielcarek N
FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
[TBL] [Abstract][Full Text] [Related]
9. Human T-cell immunity against Bordetella pertussis analyzed at clonal level.
Tagliabue A; De Magistris MT; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():253-7. PubMed ID: 2908527
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of acellular pertussis vaccines].
Wirsing von König CH; Finger H
Immun Infekt; 1995 Aug; 23(4):125-9. PubMed ID: 7558115
[TBL] [Abstract][Full Text] [Related]
11. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
[TBL] [Abstract][Full Text] [Related]
12. Progress towards the development of new vaccines against whooping cough.
Rappuoli R; Podda A; Pizza M; Covacci A; Bartoloni A; de Magistris MT; Nencioni L
Vaccine; 1992; 10(14):1027-32. PubMed ID: 1471424
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
[TBL] [Abstract][Full Text] [Related]
14. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L
Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545
[TBL] [Abstract][Full Text] [Related]
15. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
Ryan M; Gothefors L; Storsaeter J; Mills KH
Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
[TBL] [Abstract][Full Text] [Related]
16. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
Rappuoli R
Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
[TBL] [Abstract][Full Text] [Related]
17. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Kuno-Sakai H; Kimura M; Watanabe H
Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of genetically inactivated pertussis toxin.
Brown DR; Keith JM; Sato H; Sato Y
Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
[TBL] [Abstract][Full Text] [Related]
19. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
[TBL] [Abstract][Full Text] [Related]
20. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
